Please select the option that best describes you:

How would you consolidate a patient with primary refractory double hit lymphoma with secondary CNS involvement?  

At the time of initial diagnosis, there was no clear CNS involvement. When it became clinically apparent disease was refractory to EPOCH, there was CSF involvement. Now clinically responding to R-DHAOx. Would you extrapolate from studies like ZUMA-7 and TRANSFORM and go to CART, or consider thiotepa-based auto if CR is achieved? Limited co-morbidities and excellent performance status. 



Answer from: at Academic Institution

Answer from: Medical Oncologist at Academic Institution